2024-05-01T08:58:07-05:00 2023-12-31 050409384 KAHN LITWIN RENZA & CO LTD 951 NORTH MAIN STREET PROVIDENCE RI 02904 990 2023-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION ALZH 7812373800 34 WASHINGTON ST 310 WELLESLEY HILLS MA 02481 MARGARET E SMITH CEO 7812373800 2024-04-30 1 MARGARET SMITH 999009999 1 SANDY ROSS P01399337 4012742001 2024-04-26 2 AAL1 IAL1 2023 2023-04-26 12:10:37Z CURE ALZHEIMER'S FUND MARGARET E SMITH 34 WASHINGTON ST 310 WELLESLEY HILLS MA 02481 46196573 0 X HTTP://CUREALZ.ORG/ X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. 7 6 36 85 0 0 32354655 36697205 0 0 8359727 1042285 -6137 -14283 40708245 37725207 23431727 26431117 0 0 3951303 4878104 0 0 1897310 3229984 3324327 30613014 34633548 10095231 3091659 30192784 33488279 1734174 1727324 28458610 31760955 TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. ALL OVERHEAD EXPENSES ARE PAID BY THE BOARD OF DIRECTORS, TRUSTEES AND CORE GROUP OF SELECT DONORS, ALLOWING 100% OF GENERAL DONATIONS TO FUND OUR RESEARCH PROGRAMS. 0 0 27793083 26431117 IN 2023, CURE ALZHEIMER'S FUND SUPPORTED 114 RESEARCH PROJECTS AT 53 LEADING RESEARCH INSTITUTIONS, FOR RESEARCH OUTPUT OF MORE THAN $27.7 MILLION. MANY PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT, IN PARTICULAR REGARDING THE ROLE OF THE GUT MICROBIOME AND IMMUNE SYSTEM IN HEALTHY BRAIN FUNCTION. ADDITIONAL EXPENSES INCLUDE HUSBANDRY OF TRANSGENIC ANIMAL MODELS BY A CONTRACT RESEARCH ORGANIZATION; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THE AWARD PROCESS; AND COSTS ASSOCIATED WITH ASSESSING RESEARCH PROPOSALS AND DETERMINING FUNDING PRIORITIES. 3607458 CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. 31400541 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 30 0 1 36 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 7 6 1 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X X MARGARET E SMITH 7812373800 34 WASHINGTON STREET STE 310 WELLESLEY HILLS MA 02481 MARGARET SMITH CEO (AS OF 10/23) 40.00 X X 321513 0 28490 HENRY MCCANCE CHAIR 5.00 X X 0 0 0 JACQUELINE MORBY DIRECTOR 5.00 X 0 0 0 ROBERT GREENHILL DIRECTOR 5.00 X 0 0 0 RICHARD BIRNBAUM DIRECTOR (AS OF 7/23) 5.00 X 0 0 0 JEFFREY MORBY DIRECTOR (DECEASED 9/23) 20.00 X 0 0 0 TIMOTHY ARMOUR FORMER PRESIDENT & CEO (TO 09/23) 40.00 X X 350862 0 10860 LAUREL LYLE SECRETARY & VP BOARD RELAT 30.00 X X 113594 0 3982 PHYLLIS RAPPAPORT TREASURER 2.00 X X 0 0 0 JOSEPHINE ANTONELLIS CHIEF FINANCIAL OFFICER (AS OF 8/23) 30.00 X 150986 0 5543 KATHARINE HERMAN EVP DEVELOPMENT 40.00 X 405657 0 30315 BARBARA CHAMBERS EVP MARKETING & COMM. 40.00 X 254908 0 22740 DANIEL HARPER SENIOR PHILANTHROPIC ADVISOR 40.00 X 181380 0 11960 MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR 40.00 X 168942 0 25164 JOHN SLATTERY SVP MAJOR GIFTS 40.00 X 190709 0 6713 KELLY WESTERHOUSE VP LEADERSHIP GIVING 40.00 X 155421 0 10356 LISA RAND VP MARKETING & COMM. 40.00 X 193830 0 18277 2487802 0 174400 16 0 1 0 PROPER VILLAINS LLC 855 BOYLSTON STREET 10TH FLOOR BOSTON MA 02116 CREATIVE AND PRODUCTION SERVICES 257856 SPENCER STUART 353 NORTH CLARK STREET SUITE 2400 CHICAGO IL 60654 RECRUITING CEO SEARCH 180566 GRYPHON CONSULTING LLC 21 DEAN ST BELMONT MA 02478 FINANCIAL & MGT CONSULTANT 125651 3 199600 36497605 8382433 36697205 992260 992260 8436908 8386883 50025 50025 50025 70200 199600 84483 -14283 -14283 37725207 0 0 1028002 23118277 23118277 3312840 3312840 1736973 1010353 355663 370957 2586851 1423565 371733 791553 68504 39467 8979 20058 182234 95435 34395 52404 303542 170378 51703 81461 69536 7989 55337 6210 105190 105190 78000 78000 14857 14857 560597 235251 164943 160403 727294 700412 26882 192314 73256 37420 81638 77392 9383 68009 199250 114272 32882 52096 134887 58136 1540 75211 273478 260906 12572 3042 3042 26714 4403 20304 2007 RESEARCH LAB EXPENSES 659485 659485 GIFT PROCESSING FEES 147164 147164 MISCELLANEOUS 55127 28733 9700 16694 34633548 31400541 1335697 1897310 2778505 1219384 7254987 3993426 1877735 3783152 218532 239429 54458 54458 3042 0 17733326 24112740 326657 140148 30192784 33488279 129949 316299 763585 718427 840640 692598 1734174 1727324 X 26297281 27791118 2161329 3969837 28458610 31760955 30192784 33488279 3091659 210686 0 X X 0 1 X 1 0 X 30497342 22874388 26547838 32354655 36697205 148971428 30497342 22874388 26547838 32354655 36697205 148971428 17584394 131387034 83306 15472 4497 93408 992260 1188943 150160371 213300 0.87500 0.88510 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 78000 0 0 78000 0 PART II-B, LINE 1(G) A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. 7767 7767 0 46691 46691 0 0 ACCRUED PAYROLL AND RELATED 566892 LEASE PAYABLE 125706 692598 X 37921036 210686 210686 37710350 14857 14857 37725207 34618691 0 34618691 14857 14857 34633548 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVELS. THE ORGANIZATION ANNUALLY FILES IRS FORM 990 RETURNS OF ORGANIZATIONS EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH _ 0 2284252 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 540155 EAST ASIA AND THE PACIFIC 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 488433 0 0 0 0 0 0 3312840 0 3312840 BELGIUM IDENTIFYING MEDIATORS OF TAU MEDIATED NEURONAL NECROPTOSIS USING AN INNOVATIVE IN VIVO CRISPR SCREEN 230000 ACH 0 FINLAND NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE 11500 ACH 0 GERMANY SIGNALING FUNCTION OF TREM2 CLEAVAGE PRODUCTS, WHICH ARE AFFECTED BY AGONISTIC ANTIBODIES TO THE STALK REGION 172500 ACH 0 GERMANY CSF NEUROINFLAMMATORY SIGNATURE IN ALZHEIMER'S DISEASE AND RELATED PROTEOPATHIES 180550 ACH 0 GERMANY ADDING GENOMICS AND METHYLOMICS TO PERSONALIZED DISEASE PREDICTION FOR ALZHEIMER'S DISEASE (EPIC4AD) 116684 ACH 0 GERMANY CHARACTERIZATION OF THE LONGITUDINAL TRAJECTORIES OF THE SYNAPTIC BLOOD MARKER -SYNUCLEIN DURING AD PATHOGENESIS AND IMPROVEMENT OF THE MEASUREMENT PROCEDURE 144325 ACH 0 HONG KONG APOE CONSORTIUM: APOE GENOTYPE-SPECIFIC EFFECTS OF HUMAN YOUNG PLASMA ON CEREBROVASCULATURE AND AD PATHOLOGY 287500 ACH 0 ISRAEL DECODING MICROBIAL PRODUCTS MODULATING ALZHEIMER'S DISEASE - TOWARDS PRECISION POSTBIOTICS TREATMENT 201250 ACH 0 ISRAEL A PROPOSAL TO EVALUATE THE EFFECT OF BCG VACCINATION ON ALZHEIMER'S DISEASE DEVELOPMENT 223100 ACH 0 ISRAEL UNDERSTANDING THE MECHANISM UNDERLYING VACCINATION FOR ALZHEIMER'S DISEASE 115805 ACH 0 ITALY EXTRACELLULAR ATP IS A KEY FACTOR IN PROMOTING ALZHEIMER'S DISEASE NEUROINFLAMMATION 150000 ACH 0 NETHERLANDS DISENTANGLING THE ROLE OF INTRACRANIAL ARTERIOSCLEROSIS IN ALZHEIMER'S DISEASE 167207 ACH 0 NETHERLANDS UNDERSTANDING THE DYNAMIC LIPID-IMMUNOMETABOLOME OF PROTECTIVE AND RISK ALZHEIMER MICROGLIA 201250 ACH 0 NEW ZEALAND CHARACTERIZATION AND VALIDATION OF TWO RECENTLY CREATED SHEEP MODELS OF ALZHEIMER'S DISEASE IN PREPARATION FOR USE AS A PRECLINICAL PHARMACEUTICAL TESTING MODELS 200933 ACH 0 SWEDEN CHARACTERIZATION OF TAU PATHOLOGY HETEROGENEITY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM 201250 ACH 0 UNITED KINGDOM INFLUENCE OF PLAQUE VICINITY ON MICROGLIAL AND ASTROCYTE GENE EXPRESSION; ROLE OF HUMAN TAU AND TREM2 172369 ACH 0 UNITED KINGDOM SCALING THE DIVIDE IN ALZHEIMER'S DISEASE: AN INTEGRATED MOLECULAR, CELLULAR AND NETWORK-LEVEL STUDY 191624 ACH 0 UNITED KINGDOM ADTC: IMPACT OF TAU MUTATIONS AND A ON TAU POST-TRANSLATIONAL MODIFICATIONS AND CONFORMATION 344993 ACH 0 15 0 0 0 0 0 0 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. FISHER ISLAND GOLF 269800 199600 70200 52000 4793 27690 269800 199600 70200 52000 4793 27690 84483 -14283 1 BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501 (C)(3) 118450 0 AGP: GENOMIC VARIANT CALLING AND DATA MANAGEMENT FOR THE CURE ALZHEIMER'S FUND ALZHEIMER'S GENOME PROJECT BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501 (C)(3) 344085 0 NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501 (C)(3) 189750 0 NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE BOSTON UNIVERSITY 881 COMMONWEALTH AVE BOSTON MA 02215 042103547 501 (C)(3) 287500 0 APOE CONSORTIUM: MODULATION OF SELECTIVE NEURONAL VULNERABILITY IN ALZHEIMER'S DISEASE BY APOE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 287500 0 APOE CONSORTIUM: APOE4-MEDIATED DYSFUNCTION OF CD8 T CELL-MICROGLIA CROSSTALK IN ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 287500 0 MBC: HARNESSING DIET-MICROBE INTERACTIONS TO PREVENT ALZHEIMER'S DISEASE PATHOGENESIS BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 201250 0 TARGETING NEUROINFLAMMATION WITH NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO TREAT ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 201250 0 ROLE OF CHECKPOINT MOLECULES TIM-3 AND LAG-3 IN MICROGLIAL FUNCTION IN ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 431250 0 A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02111 042312909 501 (C)(3) 201250 0 NEUROIMMUNE CONNECTOME PERTURBATIONS IN ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 201250 0 TARGETING THE MICROBIOME AND INNATE IMMUNITY IN ALZHEIMER'S DISEASE BROAD INSTITUTE 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501 (C)(3) 172550 0 REVEALING NEW GENES AND PATHWAYS AT THE INTERSECTION OF LIPOTOXIC AND GENETIC RISK FOR ALZHEIMER'S DISEASE COLUMBIA UNIVERSITY 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 135598093 501 (C)(3) 201250 0 NONCODING TRANSLATION FEEDBACK LOOP IN ALZHEIMER'S DISEASE COLUMBIA UNIVERSITY 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 135598093 501 (C)(3) 201501 0 NEUROPROTEASOMES MECHANISTICALLY CONNECT APOE ISOFORMS TO ENDOGENOUS TAU AGGREGATION DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL STREET SUITE 900 DURHAM NC 27701 560532129 501 (C)(3) 229994 0 UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL STREET SUITE 900 DURHAM NC 27701 560532129 501 (C)(3) 195434 0 CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR ATLANTA GA 30322 580566256 501 (C)(3) 201250 0 MITOCHONDRIAL ALZHEIMER'S RISK FACTORS CONTROL APOE EXPRESSION AND SECRETION HARVARD MEDICAL SCHOOL 1033 MASSACHUSETTS VE 3RD FLOOR BOSTON MA 02138 042103580 501 (C)(3) 40250 0 GENETIC ANCESTRY-SPECIFIC RISK ESTIMATION OF ALZHEIMER'S DISEASE (AD) IN THE APOE REGION HARVARD MEDICAL SCHOOL 1033 MASSACHUSETTS VE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 150000 0 PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA HARVARD MEDICAL SCHOOL 1033 MASSACHUSETTS VE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 220071 0 ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE ICAHN SCOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 172500 0 IN VIVO MODELS FOR GOLGI FRAGMENTATION AND THE MOLECULAR PATHOGENESIS OF ALZHEIMER'S DISEASE ICAHN SCOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 172500 0 STRESS AND NEUROVASCULAR-IMMUNE NETWORKS IN ALZHEIMER'S DISEASE ICAHN SCOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 201250 0 INVESTIGATING MEF2C TRANSCRIPTION FACTOR AS THERAPEUTIC TARGET TO REPROGRAM PATHOLOGICAL MICROGLIAL STATES IN ALZHEIMER'S DISEASE ICAHN SCOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 172500 0 INVESTIGATING BONE MARROW HEMATOPOIESIS AND THE LINK BETWEEN SLEEP FRAGMENTATION AND VASCULAR INFLAMMATION IN AD ICAHN SCOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 201250 0 INVESTIGATING LYSOSOMAL MECHANISMS OF RISK AND RESILIENCE IN ALZHEIMER'S DISEASE JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE MD 21205 520595110 501 (C)(3) 201250 0 HUMAN BRAIN CD33 LIGAND, RPTPS3L, LIMITS MICROGLIAL PHAGOCYTOSIS AND CONTRIBUTES TO ALZHEIMER'S DISEASE PROGRESSION MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 1955000 0 THE CUREALZ ALZHEIMER'S GENOME PROJECT MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 172500 0 TAU AND -AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 172000 0 REGIONAL VARIABILITY OF PATHOLOGY-ASSOCIATED PROPERTIES OF TAU IN POSTERIOR CORTICAL ATROPHY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 ROLE OF STABILIZATION OF MAMS AND MAM-ASSOCIATED PALMITOYLATED APP (MAM-PALAPP) IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 230000 0 BEE: A 3D IN-VITRO NEURO-VASCULAR HUMAN BRAIN MODEL WITH MENINGEAL LYMPHATICS FOR ELUCIDATING MECHANISMS UNDERLYING ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 ROLE OF RIN3 AND BIN1 INTERACTION IN THE NEURONS FOR ALZHEIMER'S DISEASE DEVELOPMENT MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 CHARACTERIZING GUT BACTERIOME-MYCOBIOME SYNERGY IN CORRELATION TO AMYLIN-A ANTIMICROBIAL SYNERGY IN ALZHEIMER'S DISEASE (AD) IN AD MOUSE MODELS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 287169 0 ADTC: HOW DO SOLUBLE TAU SPECIES REPLICATE? MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 125000 0 THE IMPACT OF MUTATIONS IN THE LIGAND-BINDING DOMAIN OF CD33 ON ALZHEIMER'S DISEASE PATHOGENESIS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 300000 0 UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 345000 0 NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 VALIDATION AND CHARACTERIZATION OF COMPOUNDS MODULATING NEUROINFLAMMATION AND AMYLOID BETA UPTAKE IN MICROGLIAL CELLS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 258750 0 FUNCTIONAL CHANGES TO CEREBROSPINAL FLUID IMMUNE CELLS RESULTING FROM BACILLUS CALMETTE-GURIN (BCG) VACCINATION IN OLDER ADULTS WITH AND WITHOUT ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 CHARACTERIZATION OF CNS-PENETRANT HDAC11-SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 95594 0 GENERAL SCIENTIFIC SUPPORT MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 GROWTH, CHARACTERIZATION, AND DISTRIBUTION OF A NEURODEGENERATIVE DISEASE-FOCUSED FIBROBLAST/IPS CELL BANK TO SUPPORT MOLECULAR MODELS OF PATIENT-SPECIFIC VARIATION WITH VALIDATION IN MATCHED DONATED BRAIN TISSUES MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 287500 0 MBC: MICROBIAL PROFILING OF HUMAN BRAIN AND GUT MICROBIOMES IN ALZHEIMER'S DISEASE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501 (C)(3) 300000 0 CIRCUITS: DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 32224 593337028 501 (C)(3) 201250 0 RESTORE MENINGEAL LYMPHATIC DRAINAGE TO ALLEVIATE WHITE MATTER DAMAGE AND CEREBRAL AMYLOID ANGIOPATHY IN A MODEL OF ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 32224 593337028 501 (C)(3) 201250 0 ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 32224 593337028 501 (C)(3) 172500 0 TARGETING MICROGLIAL TSG 101 FOR SYNAPTIC PROTECTION AND COGNITIVE ENHANCEMENT IN ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 32224 593337028 501 (C)(3) 201250 0 EVALUATING TMEM106B ACCUMULATION IN AD MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 32224 593337028 501 (C)(3) 201250 0 ELUCIDATING THE PROTECTIVE EFFECTS OF APOE2 IN THE PRESENCE OF APOE4 GENE ALLELE IN ANIMAL MODELS MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK NY 10065 131924236 501 (C)(3) 230000 0 THE ROLE OF IFITM3 AND Y-SECRETASE IN MICROGLIA NEW YORK UNIVERSITY 550 FIRST AVE NEW YORK NY 10016 135562308 501 (C)(3) 208033 0 MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE CHICAGO IL 60611 362167817 501 (C)(3) 172500 0 T CELL EPIGENETICS IN ALZHEIMER'S DISEASE NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE CHICAGO IL 60611 362167817 501 (C)(3) 345000 0 MBC: INTERACTION OF THE MICROBIOME WITH ASTROCYTES AND AMYLOID PATHOLOGY NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE CHICAGO IL 60611 362167817 501 (C)(3) 286448 0 ADTC: THE ROLE OF A-INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE CHICAGO IL 60611 362167817 501 (C)(3) 136827 0 INTERROGATING LEVETIRACETAM'S IMPACT ON AMYLOID PATHOLOGY AND PRESYNAPTIC PROTEOSTASIS IN KNOCK-IN MOUSE MODELS WITH HUMANIZED ABETA STANFORD UNIVERSITY 485 BROADWAY REDWOOD CITY CA 94063 941156365 501 (C)(3) 201250 0 MULTIOMICS CHARACTERIZATION OF TAU PATHOLOGY ONSET AND ITS RELATIONSHIP WITH AMYLOID IN THE HUMAN HIPPOCAMPUS STANFORD UNIVERSITY 485 BROADWAY REDWOOD CITY CA 94063 941156365 501 (C)(3) 198751 0 OLIGODENDROGLIAL DYNAMICS AND MYELINATION IN ALZHEIMER'S DISEASE THE METHODIST HOSPITAL FOUNDATION PO BOX 4384 HOUSTON TX 77210 760094743 501 (C)(3) 201199 0 A MUTI-MODALITY STUDY ON LIPID MOLECULAR BASIS OF OBESITY AND ITS ROLES IN REGULATING ALZHEIMER'S PATHOGENESIS FOR DEVELOPING POTENTIAL TARGETED INTERVENTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORMIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 94143 943067788 501 (C)(3) 201250 0 NEURONAL MECHANISMS DRIVING SYNAPSE LOSS IN ALZHEIMER'S DISEASE THE SALK INSTITUTE FOR BIOLOGIAL STUDIES 10010 NORTH TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 201250 0 TO ELUCIDATE THE ROLE OF MEMORY T CELLS AS A DETERMINANT OF AGE-RELATED INFLAMMATION IN ALZHEIMER'S DISEASE THE SALK INSTITUTE FOR BIOLOGIAL STUDIES 10010 NORTH TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 172500 0 THE ROLE OF ASTROCYTE-SECRETED IGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE TUFTS UNIVERSITY 136 HARRISON AVENUE BOSTON MA 02111 042103634 501 (C)(3) 201250 0 MULTIDISCIPLINARY PHENOTYPING OF A NOVEL HUMANIZED LOAD MOUSE MODEL UNIVERSITY OF CALIFORNIA IRVINE 120 THEORY SUITE 200 IRVINE CA 92697 952226406 501 (C)(3) 287493 0 NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS UNIVERSITY OF CALIFORNIA IRVINE 120 THEORY SUITE 200 IRVINE CA 92697 952226406 501 (C)(3) 230000 0 ENDOGENOUS HUMAN ANTIBODIES ASSOCIATED WITH ALZHEIMER'S DISEASE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0721 LA JOLLA CA 92093 952872494 501 (C)(3) 287500 0 NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE BSB3092 LA JOLLA CA 92093 952872494 501 (C)(3) 230000 0 APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER'S DISEASE IN DOWN SYNDROME UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE DEPT 0651 LA JOLLA CA 92093 952872494 501 (C)(3) 287500 0 BEE: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMER'S DISEASE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVE CHICAGO IL 60637 362177139 501 (C)(3) 250000 0 MBC: TEMPORAL RELATIONSHIPS BETWEEN GUT DYSBIOSIS, BRAIN AB METABOLISM AND MICROGLIA CELL ACTIVATION FOLLOWING ANTIBIOTIC TREATMENT UNIVERSITY OF CONNECTICUT 263 FARMINGTON AVE FARMINGTON CT 06053 060772160 501 (C)(3) 230000 0 AD PATHOPHYSIOLOGY ALTERS THE LEVEL OF ELECTRICAL AND CHEMICAL SYNAPSE COUPLING IN THE NETWORK OF GABAERGIC PV+ INTERNEURONS EARLY IN DISEASE COURSE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR MI 48109 386006309 501 (C)(3) 201250 0 MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR MI 48109 386006309 501 (C)(3) 57500 0 IN VIVO MODELS FOR GOLGI FRAGMENTATION AND THE MOLECULAR PATHOGENESIS OF ALZHEIMER'S DISEASE UNIVERSITY OF RHODE ISLAND 75 LOWER COLLEGE ROAD KINGSTON RI 02881 223011455 501 (C)(3) 201250 0 EFFECT OF APOE GENOTYPE IN A NOVEL RAT MODEL OF CEREBRAL AMYLOID ANGIOPATHY UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA STREET SUITE 102 LOS ANGELES CA 90089 951642394 501 (C)(3) 201250 0 PRENATAL INFLAMMATION EFFECTS ON BLOOD BRAIN BARRIER FUNCTION AND AD-RELATED PATHOLOGIES ACROSS THE LIFESPAN UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA STREET SUITE 102 LOS ANGELES CA 90089 951642394 501 (C)(3) 301069 0 AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA STREET SUITE 102 LOS ANGELES CA 90089 951642394 501 (C)(3) 234709 0 PROTECTION AGAINST APOE4 WITH LONGEVITY-PROMOTING INTERVENTIONS UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA STREET SUITE 102 LOS ANGELES CA 90089 951642394 501 (C)(3) 250000 0 CELLULAR AND MOLECULAR STUDIES OF APOE REGULATION OF BLOOD-BRAIN BARRIER, SYNAPTIC AND NEURONAL FUNCTIONS AND PROTECTION STRATEGIES IN MOUSE MODELS WITH AND WITHOUT ALZHEIMER'S PAHTOLOGY UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE SAN ANTONIO TX 78229 741586031 501 (C)(3) 201250 0 IDENTIFICATION AND VALIDATION OF PLASMA-BASED LIPID BIOMARKERS FOR EARLY ALZHEIMER'S DISEASE IN THE UNIQUE, PRIMARILY HISPANIC, SOUTH TEXAS POPULATION UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 752556007 501 (C)(3) 287000 0 ADTC: ROLE OF VCP/P97 IN TAU PRION REPLICATION UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 752556007 501 (C)(3) 230000 0 RNA AS A DETERMINANT OF TAU SEEDING UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE VA 22904 546001796 501 (C)(3) 192020 0 TOXIC EFFECTS OF EXTRACELLULAR TAU OLIGOMERS ON NEURONS UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE VA 22904 546001796 501 (C)(3) 201250 0 ELUCIDATING THE ROLE OF CLEC7A IN TAU-MEDIATED NEURODEGENERATIVE DISEASE UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE VA 22904 546001796 501 (C)(3) 201250 0 EXPLORING THE THERAPEUTIC POTENTIAL OF CLUSTERIN IN A PRECLINICAL MODEL OF ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 113655 0 CHARACTERIZATION OF MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 287500 0 MBC: THE ROLE OF GUT MICROBIAL METABOLISM IN TAU-MEDIATED NEURODEGENERATION WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 172500 0 UNDERSTANDING THE ROLE OF NATURAL A-SPECIFIC B CELL RESPONSES IN AD PROGRESSION WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 189902 0 DECIPHERING AND RESTORING COMPUTATIONAL SET-POINTS IN ALZHEIMER'S DISEASE THROUGH SLEEP-ENHANCED NETWORK HOMEOSTASIS WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 345000 0 BEE: CROSSTALK OF CNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 345000 0 APOE CONSORTIUM: ROLE OF APOE ISOFORMS IN IMMUNE RESPONSES IN A MODEL OF TAUOPATHY WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201248 0 ANTIVIRAL T CELLS INFILTRATION TO THE MENINGES AND BRAIN INFLUENCES NEURODEGENERATION IN ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 DISSECTING ALZHEIMER'S DISEASE PHENOTYPES IN DIRECTLY REPROGRAMMED PATIENT-DERIVED NEURONS WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 198994 0 CIRCADIAN DESYNCHRONY, GLIAL DYSFUNCTION, AND ALZHEIMER'S DISEASE PATHOGENESIS WEILL CORNELL 1300 YORK AVENUE NEW YORK NY 10065 136094042 501 (C)(3) 201250 0 IDENTIFICATION AND DEVELOPMENT OF CD33 INHIBITORS AND PRE-RNA SPLICING MODULATORS WEILL CORNELL 1300 YORK AVENUE NEW YORK NY 10065 136094042 501 (C)(3) 250000 0 DEVELOPMENT OF HUMAN CGAS INHIBITORS TO TREAT ALZHEIMER'S DISEASE WEILL CORNELL 1300 YORK AVENUE NEW YORK NY 10065 136094042 501 (C)(3) 201250 0 TAU-INDUCED POSTSYNAPTIC DYSFUNCTION IN TAUOPATHY MODELS WEILL CORNELL 1300 YORK AVENUE NEW YORK NY 10065 136094042 501 (C)(3) 287500 0 BEE: BIOCHEMICAL AND FUNCTIONAL ANALYSIS OF CSF AND LYMPH FOLLOWING CHANGES IN BRAIN FLUID DYNAMICS YALE UNIVERSITY PO BOX 208239 NEW HAVEN CT 06520 060646973 501 (C)(3) 204081 0 BEE: CNS FLUID HOMEOSTASIS AND WASTE CLEARANCE IN ALZHEIMER'S DISEASE CHARACTERIZED BY MRI 36 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. X X X X X X 0 0 0 0 0 0 0 0 0 KATHARINE HERMAN EVP DEVELOPMENT 405657 0 0 0 0 0 9900 0 20415 0 435972 0 0 0 TIMOTHY ARMOUR FORMER PRESIDENT & CEO (TO 09/23) 350862 0 0 0 0 0 9900 0 960 0 361722 0 0 0 MARGARET SMITH CEO (AS OF 10/23) 321513 0 0 0 0 0 9900 0 18590 0 350003 0 0 0 BARBARA CHAMBERS EVP MARKETING & COMM. 254908 0 0 0 0 0 8001 0 14739 0 277648 0 0 0 LISA RAND VP MARKETING & COMM. 193830 0 0 0 0 0 6088 0 12189 0 212107 0 0 0 JOHN SLATTERY SVP MAJOR GIFTS 190709 0 0 0 0 0 5813 0 900 0 197422 0 0 0 MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR 168942 0 0 0 0 0 5439 0 19725 0 194106 0 0 0 DANIEL HARPER SENIOR PHILANTHROPIC ADVISOR 181380 0 0 0 0 0 5565 0 6395 0 193340 0 0 0 KELLY WESTERHOUSE VP LEADERSHIP GIVING 155421 0 0 0 0 0 4819 0 5537 0 165777 0 0 0 JOSEPHINE ANTONELLIS CHIEF FINANCIAL OFFICER (AS OF 8/23) 150986 0 0 0 0 0 4537 0 1006 0 156529 0 0 0 SCHEDULE J, PART I, LINE 3 AN EXECUTIVE SEARCH FIRM WAS HIRED TO RECRUIT THE NEW CEO. THEY ALSO PROVIDED AN INDEPENDENT COMPENSATION CONSULTATION. WHEN THE NEW CEO CAME ON BOARD A WRITTEN EMPLOYMENT CONTRACT WAS CREATED. PROPER VILLIANS LLC A PRINCIPAL OF THE INDEPENDENT CONTRACTOR IS THE SPOUSE OF A KEY EMPLOYEE 257856 CREATIVE AND PRODUCTION SERVICES 0 X 42 8382433 SALE PRICE 0 0 0 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH FIRST REPUBLIC BANK AND BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION A, LINE 2 JEFFREY MORBY (DECEASED 9/2023) AND JACQUELINE MORBY WERE BOTH DIRECTORS AND SPOUSES. FORM 990, PART VI, SECTION A, LINE 4 THE ORGANIZATION MADE CHANGES TO THE BYLAWS AND ARTICLES OF INCORPORATION TO UPDATE FOR CURRENT LANGUAGE AND BEST PRACTICES. THIS INCLUDED REMOVING LIMITS ON THE TOTAL NUMBER OF DIRECTORS AND MOVING FROM NAMES TO TITLES FOR STAFF POSITIONS. THE ARTICLES OF INCORPORATION WERE UPDATED TO ESTABLISH CUREALZ'S FULL INDEPENDENCE. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE CEO AND ALL OTHER EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE. FORM 990, PART XII, LINE 2C THE ORGANIZATION DID NOT CHANGE EITHER ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR.